Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Phase I trial of ribociclib in combination with everolimus and dexamethasone in children and young adults with relapsed acute lymphoblastic leukemia

Principal Investigator: Twist, Clare J

(ACNS1723) A Phase 2 Study of Dabrafenib (NCS#763760) with Trametinib (NCS# 763093) after Local Irradiation in Newly-Diagnosed BRAFv600-Mutant High-Grade Glioma (HGG) (IND#145355)

Principal Investigator: Twist, Clare J

Endobronchial Ultrasound Transbronchial Needle Guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer in the Central Airway

Principal Investigator: Ivanick, Nathaniel M

HCRN GI17-319: A single arm, multi-center Phase 2 trial of mFOLFOX6 + trastuzumab + avelumab in first-line, metastatic, HER2-amplified gastric and esophageal adenocarcinomas

Principal Investigator: Mukherjee, Sarbajit

A phase 1b/2a, open label study to evaluate anti-tumor efficacy and safety of rhIL-7-hyFc (NT-I7) in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory high-risk skin cancers

Principal Investigator: Ernstoff, Marc S

A Phase I/II Study of Carfilzomib in Combination with R-CHOP (CR CHOP) for Patients with Diffuse Large B-Cell Lymphoma

Principal Investigator: Torka, Pallawi

( LX1606.1-207-BTC ) A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) plus First-line Chemotherapy in Patients with Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)

Principal Investigator: Iyer, Renuka V

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

Principal Investigator: Kelly, Kara M

A phase Ib/2 study of IMGN632 as monotherapy or combination with venetoclax and/or azacitidine for patients with CD123+ AML

Principal Investigator: Wang, Eunice S

(GRASPANC 2018-01) A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma TRYbeCA-1 TRial of erYaspase in pancreatic Cancer.

Principal Investigator: Fountzilas, Christos

A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone,Vincristine,Methotrexate,6 Mercaptopurine) for Pts >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Neg (Ph-) ALL and of Dasatinib (NSC 732517) , Prednisone and…

Principal Investigator: Wang, Eunice S

A Phase 1 Study of Milademetan in combination with Quizartinib in subjects with FLT3 ITD mutant Acute Myeloid Leukemia that are relapsed/refractory, or newly diagnosed and unfit for intensive chemotherapy

Principal Investigator: Wang, Eunice S

AHOD1721, Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin(N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 +classic Hodgkin lymphoma (cHL) after failure of first-line…

Principal Investigator: Kelly, Kara M

An Open-label Phase 1 Study to Assess the Safety, Tolerability,
Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy
of MEDI5395 in Combination with Durvalumab in Subjects with
Select Advanced Solid Tumors

Principal Investigator: Dy, Grace K

EA4181, A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in…

Principal Investigator: Torka, Pallawi

(ASTX660-01) Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti-PD-a/ PD-L1 Based Immunotherapy

Principal Investigator: George, Saby

EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response

Principal Investigator: Levine, Ellis G

(ACCL1333/CV185-155) A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed…

Principal Investigator: Bambach, Barbara J

A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible

Principal Investigator: Chatta, Gurkamal S

(BMT CTN Protocol 1507) Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease

Principal Investigator: Balderman, Sophia R

An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (ASM)

Principal Investigator: Elshoury, Amro

A Pilot Study of Photoacoustic Imaging (PAI)

Principal Investigator: Singh, Anurag K

A Phase 1/2, Multicenter, Open-Label, Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Principal Investigator: Wang, Eunice S

Preoperative Respiratory Muscle Training to Prevent Postoperative Pulmonary Complications in Patients Undergoing Resection for Lung Cancer

Principal Investigator: Yendamuri, Sai S